Alcohol and Anabolic Steroids
The use of anabolic steroids is often associated with the pursuit of physical performance and aesthetic changes, while alcohol consumption is frequently seen as routine and socially acceptable. However, combining the two raises a warning sign. More recent studies show that, although there are still gaps in understanding the exact mechanisms of this interaction, the concurrent use of alcohol and anabolic steroids may increase the burden on the liver and be part of a broader context of risk behaviors, with consequences that go beyond liver health and include cardiovascular, hormonal, and psychiatric effects.
The non-medical use of anabolic androgenic steroids has grown in various contexts, far beyond professional sports. Today, this use is seen among gym-goers, amateur bodybuilders, and individuals motivated by aesthetic changes or improved physical performance. At the same time, alcohol remains one of the most widely consumed psychoactive substances in the world. When these two exposures overlap, an important public health concern arises: the potential combined effect on the body, especially on the liver¹.
Anabolic steroids alone are already associated with a range of adverse effects. Among the most well-known are hormonal changes, infertility, acne, gynecomastia, increased blood pressure, and mood changes. The liver is also a major concern. Recent reviews show that prolonged use at supraphysiological doses can lead to elevated liver enzymes, cholestasis, hepatic vascular alterations, and even benign or malignant liver tumors in some cases².
Alcohol, in turn, also has toxic effects on the liver and is associated with a broad spectrum of damage, ranging from steatosis to more severe forms of liver disease³. When a potentially hepatotoxic substance such as anabolic steroids is used in an organism already exposed to harmful alcohol consumption, clinical concern becomes even greater.
One of the most well-known studies on the topic analyzed data from the Drug-Induced Liver Injury Network (DILIN) in the United States, focusing on patients with drug-induced liver injury. The authors observed that among individuals with heavy alcohol consumption, anabolic steroids were prominent among the identified causes of drug-induced liver injury. This finding is relevant because it suggests that heavy alcohol use may be more common in groups where anabolic steroids already represent a risk factor for liver damage.
At the same time, the study raised an important point: the authors did not find clear evidence that heavy drinkers necessarily had worse final outcomes—such as liver-related death or the need for transplantation—compared to non-drinkers in that cohort. This does not mean the combination is safe. In practice, the findings suggest that the relationship between alcohol and anabolic steroid–related liver injury is complex and likely involves both biological and behavioral factors.
This point deserves attention. Part of the association between alcohol and anabolic steroids may reflect a broader context of risk behaviors, such as using substances without prescription, high-dose cycles, combining different compounds, and limited medical supervision²⁴. In other words, it is often not just the sum of two potentially harmful agents, but a pattern of use that already increases vulnerability to multiple health problems.
Recent literature also reinforces that the adverse effects of anabolic steroids extend far beyond the liver. A meta-analysis published in 2025 showed that abuse of these substances among athletes and physically active individuals is associated with significant increases in blood pressure and LDL cholesterol, highlighting their cardiovascular impact⁴. This broadens the discussion: individuals who use anabolic steroids and consume excessive alcohol may be exposing themselves to a combination of hepatic, metabolic, and cardiovascular risks simultaneously.
Another recent review highlighted that androgen abuse is associated with increased mortality and multisystem adverse effects, including cardiovascular toxicity, infertility, hypogonadism, hepatotoxicity, and mental health disorders³. This helps dispel the idea that anabolic steroids produce only “aesthetic” or “hormonal” effects. In reality, these substances can have wide-ranging impacts on the body, especially when used outside a medical context.
It is also important to distinguish between supervised therapeutic use and non-prescribed use. Recent studies show that individuals who use anabolic steroids without medical indication experience more adverse events than those undergoing clinically supervised testosterone therapy. This reinforces that risk is particularly concentrated in recreational, aesthetic, or performance-oriented use—often done without clinical monitoring, regular testing, or appropriate dosing, and sometimes involving unsafe combinations.
From a mental health and behavioral perspective, this combination also warrants caution. Recent reviews describe associations between anabolic steroid abuse and mood changes, aggression, impulsivity, and other psychiatric effects. Since alcohol is also linked to reduced self-control and increased exposure to accidents, violence, and risky decisions, the combination of these substances should not be viewed solely as a liver issue, but as a broader health concern.
From a prevention standpoint, the main message is clear: although more studies are needed to precisely define the biological interaction between alcohol and anabolic steroids, the existing body of evidence is sufficient to treat this combination with seriousness. It is not a trivial combination, especially when it involves heavy alcohol consumption, prolonged steroid use, oral compounds, and lack of medical supervision.
In summary, current evidence indicates that:
Informing the public about these risks is essential to counter the normalization of anabolic steroid use and excessive alcohol consumption. In public health, waiting for absolute certainty about every mechanism before issuing warnings is often a mistake. When signals of harm are already consistent, prevention remains the best course of action.
References:
Pancreas Under Pressure: The Silent Enemy of Alcohol Excess
For a long time, science has tried to unravel a major mystery: why does only a small minority of people who drink large amounts of alcohol develop acute pancreatitis?¹ The answer tells an intriguing story about how our bodies react to excess. It is important to emphasize that alcohol-related acute pancreatitis is strongly associated with chronic, heavy alcohol consumption. Moderate or occasional drinking does not cause pancreatitis. Prolonged heavy drinking leads to changes that make the pancreas vulnerable to an acute crisis.
Alcohol itself, or even the substances produced when the body processes it, cannot cause the disease on their own.² Instead, intense and prolonged alcohol consumption acts silently, reducing the pancreas’s natural chemical signaling and causing its fluids to become highly concentrated, acidic, and thick.
This situation is worsened because long periods of alcohol use are often accompanied by poor nutrition and low water intake.¹ This dehydration and relative fasting contribute to the formation of “sludge” or small protein plugs that temporarily block the tiny ducts through which pancreatic and bile fluids should flow. The danger may also arise when a person stops drinking, because after interrupting alcohol consumption and returning to normal eating—especially heavier or fatty foods—the body sends a strong signal and overstimulates the pancreas, which had been operating at a reduced pace.³ It is not the interruption of drinking or the return to normal eating that causes the crisis; rather, the crisis is triggered by the heavy alcohol intake that occurred beforehand.
Imagine a hose running at maximum pressure but with its end blocked. This is essentially what happens in the pancreas: it is forced to produce and secrete digestive juices intensely against blocked ducts.¹ Unable to flow out, these enzymes begin to act within the organ itself, effectively digesting pancreatic tissue, damaging cells, and triggering a cascade of severe inflammation. To make matters worse, continuous alcohol use weakens the pancreas’s natural defense mechanisms against this stress—an effect that is even stronger in people who also smoke.⁴
Symptoms of acute pancreatitis (severe abdominal pain, nausea, vomiting) may not appear immediately after the last drink. Pain can occur hours—or even one or two days—after excessive alcohol intake. During this interval, the person may have already stopped drinking and even tried to eat normally before symptoms become severe enough to require hospitalization. Returning to a normal diet, especially one high in fat, may simply worsen the symptoms of an already developing pancreatitis.
Acute pancreatitis is a serious medical emergency, and although medicine continues to search for treatments that can halt the disease at its origin, rapid diagnosis combined with intensive hospital support remains the most effective and safest way to stabilize the patient and save their life.
References
Parenting Styles and Substance Use: What a Study with Brazilian Families Shows
The use of alcohol, cigarettes, marijuana, and e-cigarettes among adolescents does not depend only on individual choices: parents’ behavior and the way they raise their children play a decisive role. A recent study conducted with more than four thousand adolescents in the state of São Paulo showed that, although there is a strong similarity between substance use patterns in parents and their children, this “cycle” is not inevitable. In particular, more structured and affectionate parenting styles can reduce the risk of heavy use of multiple substances during adolescence.
Adolescence is a period of greater vulnerability for initiating the use of psychoactive substances such as alcohol, tobacco, marijuana, and, more recently, e-cigarettes. These behaviors are associated with physical and mental health problems, academic difficulties, and a higher risk of dependence in adulthood. At the same time, many adolescents live with parents who also use these substances, raising the question: to what extent does parents’ use “transfer” to their children?
The study, published in the journal Addictive Behaviors, analyzed 4,280 dyads (pairs) consisting of adolescents aged 12 to 17 and their parents or guardians in four municipalities in the state of São Paulo¹. The researchers used a statistical approach called latent class analysis to identify substance use profiles among parents and adolescents, considering alcohol, binge drinking (episodes of heavy drinking), cigarettes, marijuana, and e-cigarette use. Instead of examining each drug separately, the study focused on behavioral patterns, such as abstainers, primarily alcohol users, and multiple-substance users.
Three main groups were identified among both parents and adolescents: an abstinent or very low-use group, a higher alcohol-use group, and a polysubstance use group, involving the combined use of several substances. Among parents, about half were in the low-risk group, while approximately one in eight was classified as a polysubstance user. Among adolescents, most were abstinent, but a smaller group reported recent alcohol consumption, binge drinking episodes, and use of other products, including vapes.
One of the study’s key findings was the strong correlation between parent and child profiles. When parents were abstinent, there was about a 90% probability that the adolescent would also not use substances. On the other hand, when parents belonged to the polysubstance group, the likelihood that the adolescent would also be a polysubstance user was approximately three times higher compared to children of abstinent parents. Even so, more than half of adolescents in families where parents used multiple substances remained abstinent, showing that intergenerational transmission is not automatic.
To better understand why some adolescents “escape” this family risk pattern, the study examined the role of parenting styles. Four classic styles were considered: authoritative (high warmth and high control), authoritarian (low responsiveness and high control), permissive (high warmth and low control), and neglectful (low responsiveness and low control). These styles were measured based on adolescents’ perceptions of how close their parents are, how much they communicate, set rules, and monitor behavior.
The results showed that the authoritative style had an important protective effect. Among adolescents with polysubstance-using parents, those who perceived their caregivers as authoritative were less likely to fall into the polysubstance group and more likely to remain abstinent. In other words, even when parents use substances at high levels, a parenting style that combines affection, supervision, and clear rules can significantly reduce the risk of heavy multiple-drug use during adolescence.
The authoritarian style also showed some protective effect against polysubstance use, reducing the likelihood that adolescents with high-risk parents would become polysubstance users. However, this style was associated with a greater likelihood of specific transmission of alcohol use—that is, it increased the probability that children of parents who drink would also consume alcohol. Permissive and neglectful styles did not show consistent protective effects, and in some cases estimates were limited by the small number of adolescents in certain profile combinations.
An important point is that, even in contexts with more protective parenting styles, parental alcohol consumption remained associated with a higher risk of alcohol use among adolescents. This suggests that, in the case of alcohol, the influence of modeling and normalization within the household may be particularly strong, possibly because it is a legal, widely available, and socially accepted substance.
From a public health perspective, the study highlights two key messages. First, substance use patterns are partly “inherited” within families, both in terms of risk and protection. Abstinent or low-consuming parents tend to have children who also do not use drugs, indicating that healthy behaviors can be transmitted across generations. Second, even when parents engage in risky use, more structured parenting styles—characterized by presence, warmth, and clear limits—can reduce the likelihood that adolescents will develop patterns of polysubstance use.
These findings reinforce the importance of prevention programs that involve families, not just adolescents. Interventions that strengthen parenting skills, promote dialogue, encourage consistent rules, and address beliefs about alcohol and other drugs can have a meaningful impact on reducing substance use among young people. At the same time, the study underscores that policies and actions aimed at reducing risky substance use among adults also indirectly benefit the next generation.
In summary, the article shows that:
Informing parents, educators, and policymakers about these mechanisms is essential for developing more effective prevention policies and programs aimed at reducing alcohol and other drug use during adolescence.
References
Alcohol, Calories, and Obesity: What Does the Scientific Evidence Say
The consumption of alcoholic beverages provides significant calories to the diet and may influence the risk of weight gain and obesity. Recent scientific studies show that this relationship is complex: while low alcohol intake is not always associated with weight gain, higher levels of consumption are linked to a greater likelihood of overweight and obesity, especially abdominal obesity.
Obesity is currently one of the main public health challenges worldwide. It is associated with cardiovascular diseases, diabetes, cancer, and reduced life expectancy. Among the various factors contributing to weight gain, alcohol consumption has received increasing attention from the scientific community.
Alcohol provides approximately 7 kcal per gram, an energy value close to that of fat (9 kcal/g) and higher than that of carbohydrates and proteins, both with 4 kcal/g. These calories can contribute to a positive energy balance, especially when consumption is frequent or in large amounts¹.
A comprehensive review published in the journal Critical Reviews in Food Science and Nutrition, which analyzed 127 observational studies, investigated the relationship between alcohol intake and excess weight¹. The results indicated that, in cross-sectional studies, alcohol consumption was associated with a higher likelihood of overweight and abdominal obesity. When the analysis considered the amount consumed, high intake (above 28 g of alcohol per day) was associated with a greater probability of overweight and abdominal obesity compared to non-drinkers or light drinkers. In contrast, light consumption did not show a consistent association with obesity in cohort studies.
Another meta-analysis, published in the Journal of Epidemiology and Public Health, specifically evaluated adults and found that alcohol consumption was associated with approximately a twofold increase in the likelihood of obesity in the studies included in the analysis². The study also highlighted that age influences this risk, as metabolism and physical activity patterns tend to change over the course of life.
Beyond the caloric aspect, more recent research suggests that the relationship between alcohol and obesity may go beyond simply counting calories. An article published in the journal Molecular Psychiatry discusses how alcohol and obesity share similar biological mechanisms, involving brain reward circuits, appetite regulation, gut hormones, and systemic inflammation³. This means that alcohol consumption may influence eating behavior, the feeling of satiety, and even preferences for higher-calorie foods.
Another relevant point is that alcohol can affect liver metabolism and promote fat accumulation in the liver, especially when consumed excessively. When combined with excess weight, the risk of liver disease increases significantly³. Studies show that the combination of obesity and high alcohol consumption can accelerate the development of liver diseases.
It is important to note that results vary according to the pattern of consumption. Light or occasional drinking does not show a consistent association with obesity in longitudinal studies¹. On the other hand, heavy and regular consumption is more frequently associated with weight gain and abdominal obesity, a type of body fat that carries greater cardiometabolic risk.
From a public health perspective, these findings reinforce that alcohol should be considered not only for its effects on the liver, brain, and risk of dependence, but also as a relevant source of calories in the diet. Reducing excessive consumption may contribute not only to a lower risk of alcohol-related diseases, but also to better body weight control.
In summary, scientific evidence indicates that:
The relationship between alcohol and obesity depends on dose, frequency, drinking pattern, and individual characteristics. Informing the public about this evidence is essential for making informed health decisions.
References
How Harmful Alcohol Consumption Impacts People with Heart Disease: Evidence from the PROSA Project
Alcohol consumption is a common behavior in the general population and, in some contexts, is still associated with the idea of potential cardiovascular benefits when consumed in moderation. However, recent scientific evidence shows that harmful alcohol use represents an important risk factor in people with heart disease. A Brazilian study published in 2025, conducted within the framework of the PROSA Project (Health and Alcohol Project), analyzed the relationship between lifestyle patterns and harmful alcohol consumption in patients with heart disease, bringing relevant findings for clinical practice and public health.
Harmful alcohol consumption is associated with increased morbidity and mortality, especially among individuals with cardiovascular diseases. Although light to moderate drinking has historically been described as potentially protective in some populations, this relationship does not hold when considering patterns of abusive alcohol intake, particularly in patients with established heart disease.
The PROSA Project study, published in the Arquivos Brasileiros de Cardiologia, evaluated more than 4,000 individuals¹, including patients with heart disease and volunteers without cardiopathy, using standardized instruments to measure both alcohol consumption and lifestyle behaviors. Harmful consumption was identified using the AUDIT-C test, while lifestyle was assessed through a specific score that considered factors such as smoking, physical inactivity, excess weight, anxiety, and depression.
The results showed that patients with heart disease and lifestyle behaviors classified as fair or unhealthy were more likely to engage in harmful alcohol consumption, even after adjusting for age and sex. In addition, the study demonstrated that improvements in lifestyle over time were associated with a significant reduction in abusive alcohol consumption, reinforcing the dynamic and potentially modifiable nature of this behavior.
Another relevant finding was the higher prevalence of abusive consumption among men and younger individuals, whereas prevalence was lower in older age groups. These data suggest that behavioral and psychosocial factors play a central role in alcohol consumption patterns among cardiac patients, more so than isolated clinical aspects of heart disease.
The study also highlights that abusive alcohol consumption in patients with heart disease may worsen preexisting conditions, increase the risk of arrhythmias, heart failure, and other cardiovascular events, as well as compromise treatment adherence and quality of life. Therefore, systematic lifestyle assessment emerges as an important tool to identify individuals at higher risk and to guide preventive interventions.
In conclusion, the evidence indicates that harmful alcohol consumption in people with heart disease is strongly associated with unfavorable lifestyle behaviors. Rather than being an isolated factor, alcohol is part of a broader set of habits that, when unhealthy, significantly increase cardiovascular health risks. Early identification of these behaviors and the promotion of lifestyle changes may effectively contribute to reducing abusive alcohol consumption and improving clinical outcomes in patients with heart disease.
References:
Can Weight-Loss Injection Pens Help Reduce Alcohol Consumption?
Recent research has investigated the potential of GLP-1 analogs (medications used to treat type 2 diabetes and obesity, such as semaglutide, for example) in modulating alcohol consumption. Preclinical studies indicate a reduction in alcohol intake and in the reward response associated with substance use, while clinical evidence remains preliminary and heterogeneous. This text briefly presents what science currently knows about the mechanisms involved, the results available so far, and the main challenges in applying these drugs to the treatment of alcohol use disorder (AUD).
Research on the biological effects of GLP-1 analogs (semaglutide, tirzepatide, liraglutide)—the so-called “weight-loss injection pens”—on alcohol consumption has become a relevant scientific field due to the global impact of alcohol use disorder, which is associated with high morbidity and mortality worldwide.¹² Although these glucagon-like peptide-1 receptor agonists (GLP-1RAs) were originally developed to treat type 2 diabetes and obesity, studies suggest that these medications may also act on neurobiological circuits involved in regulating the reward system, generating interest in their role in addictive behaviors.¹ ²
Preclinical studies conducted in recent years have demonstrated reduced alcohol consumption in animal models, while more recent clinical research has evaluated the translational feasibility of these findings.³ ⁴ Clinical and social interest in this field is further reinforced by the limited effectiveness and low adherence rates of currently available pharmacological therapies for alcohol use disorders, as well as by the high relapse rates observed even after treatment.⁵ ⁶
However, the main challenge lies in the still limited understanding of the biological mechanisms and clinical efficacy of GLP-1 analogs in reducing alcohol consumption, particularly in humans.⁷ ⁸ Although preclinical findings are consistent and promising, results from clinical trials remain heterogeneous and, in many cases, preliminary, with evidence of benefit restricted to specific subgroups, such as individuals with obesity.⁵ ⁹
The literature also presents inconsistencies regarding potential neuropsychiatric adverse effects, as well as differences among the various GLP-1 receptor agonists in modulating behaviors associated with alcohol consumption.¹ ¹⁰ These uncertainties highlight a knowledge gap limited by the scarcity of large-scale randomized clinical trials, incomplete understanding of additional mechanisms involved, and variability in findings across different patient profiles.⁷ ¹¹ ¹²
How Do GLP-1 Analogs Work?
GLP-1 analogs, or GLP-1 receptor agonists (GLP-1RAs), act through integrated mechanisms involving peripheral metabolic effects and central modulation of neural circuits. Physiologically, GLP-1 is an intestinal hormone released in response to food intake, promoting glucose-dependent insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake—mechanisms that support its use in treating type 2 diabetes and obesity. Evidence indicates that GLP-1 receptors also exert effects in the central nervous system, either by crossing the blood-brain barrier or through vagus nerve–mediated pathways, acting in regions involved in energy homeostasis, motivation, and reward.¹³ ¹⁴
GLP-1 receptors are distributed in brain areas such as the hypothalamus, brainstem, ventral tegmental area, and nucleus accumbens, where their activation modulates mesolimbic dopaminergic neurotransmission and reduces the reinforcing value of natural stimuli and psychoactive substances. In the context of addictive behaviors, preclinical studies show that GLP-1 signaling is associated with reduced hedonic response, decreased reward-seeking behavior, and lower alcohol consumption. Although additional mechanisms—such as modulation of neuroinflammation and stress systems—have been proposed, their clinical relevance in humans has yet to be established.¹³ ¹⁴
Final Considerations
In summary, GLP-1 analogs emerge as a potentially promising pharmacological strategy for the treatment of alcohol use disorder, given their ability to modulate neural circuits involved in reward, motivation, and substance-seeking behavior. Preclinical evidence demonstrates reduced alcohol consumption and attenuation of hedonic response (immediate reward), providing a plausible mechanistic basis for their therapeutic potential.
However, the clinical application of GLP-1 receptor agonists in the treatment of alcohol use disorder should still be considered experimental. Human studies show heterogeneous and generally preliminary results, with potential benefits possibly limited to specific subgroups, and uncertainties remaining regarding long-term safety and differences among drugs within this class. Therefore, consolidating this approach depends on large-scale randomized clinical trials that can define its efficacy, safety, and more precise clinical indications.
References:
Lifestyle, Alcohol, and Health: What Recent Studies from the Renowned Scientific Journal The Lancet Show About Mortality and Longevity
Recent studies published in journals from the The Lancet group indicate that small adjustments in everyday behaviors—such as physical activity, sleep, and diet—are associated with reduced mortality and increased years of healthy life. These findings contribute to understanding how alcohol consumption, within the broader context of lifestyle, relates to other behaviors and health outcomes over time.
A recent study published in The Lancet analyzed data from large international cohorts and estimated that modest increases in physical activity—about five additional minutes per day—were associated with a meaningful reduction in the number of deaths at the population level¹. Reductions in daily sedentary time were also associated with lower mortality. These results reinforce the importance of everyday behaviors in improving quality of life.
Alcohol consumption is part of the set of habits that characterize population lifestyles. Evidence suggests that patterns of alcohol use may influence levels of physical activity, sleep quality, and dietary choices, shaping distinct trajectories of exposure to risk and protective factors throughout life. This means that reducing alcohol consumption, alongside other beneficial lifestyle changes—such as engaging in physical activity—may have a positive impact on longevity.
Another study, published in eClinicalMedicine, a journal from The Lancet group, evaluated sleep, physical activity, and diet in an integrated manner, demonstrating that simultaneous improvements in these factors are associated with gains in both life expectancy and years lived without chronic diseases². The study highlights that the combined effects of these behaviors tend to be more significant than isolated changes.
In this context, alcohol can be understood as an intrinsic element within a set of interrelated behaviors. Different patterns of consumption coexist with varying sleep routines, levels of physical activity, and dietary habits, all influenced by social, cultural, and environmental factors. Therefore, an integrated analysis of these behaviors may allow for a broader understanding of the determinants of health and longevity.
From a public health perspective, these studies contribute to the debate on multidimensional approaches, recognizing that lifestyle-related factors—such as alcohol consumption, physical activity, sleep, and diet—do not act in isolation. Strategies based on gradual and realistic changes may promote improvements in health outcomes observed at the population level. It is important to emphasize that such strategies should respect individuals’ patterns, beliefs, and lifestyle habits, increasing the likelihood of long-term success.
In summary, recent evidence suggests that small daily adjustments, within a broader context of lifestyle habits that includes alcohol consumption, are associated with meaningful benefits for health and longevity, reinforcing the importance of integrated analyses of behavior and health.
References:
Alcohol and Antidepressants: A Mixture That Deceives the Brain
In recent decades, the use of antidepressants has grown significantly, alongside a very common cultural habit: the consumption of alcoholic beverages. This combination often occurs because anxiety and depression coexist with substance use, creating a cycle in which the patient seeks immediate relief from emotional distress through alcohol.¹ However, studies show that this interaction is far more complex and dangerous than simply reducing the medication’s effectiveness.²
One of the most intriguing findings about this combination is how the interaction between alcohol and antidepressants alters the perception of pleasure.² When a person consumes alcohol while taking certain antidepressants, such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, and escitalopram), they may not experience the typical euphoria or relaxation associated with intoxication. This phenomenon, known as “blunted pleasure,” is a dangerous trap.² Because the individual does not feel the expected effects of drinking, they may consume much larger quantities in an attempt to achieve the desired sensation. The result is a greater risk of intoxication and health damage, often without the person immediately recognizing the danger, since discomfort does not always appear right away.
Beyond subjective sensations, the body experiences silent and profound physical impacts.¹ The liver, responsible for metabolizing both medication and alcohol, may show signs of overload. In addition, alcohol can increase the side effects of antidepressants on the central nervous system, such as drowsiness and dizziness.³ Alcohol may also reduce response to antidepressant treatment and adherence, while promoting impulsivity, which can increase the risk of suicide.
Biology and behavior also show different nuances between men and women. Among women, depression is often associated with higher alcohol consumption, regardless of whether they are taking medication.⁴ Among men, antidepressant use appears to help reduce the desire to drink, suggesting a positive response to treatment or to medical guidance. Nevertheless, the golden rule for both is the same: medical supervision and honesty about one’s treatment. Hiding drinking habits makes dose adjustments more difficult and puts the effectiveness of psychiatric treatment at risk, making an integrated approach that cares for both mind and body essential.
Note: This text is for informational purposes and is based on scientific studies. It does not replace professional medical advice.
References
Alcohol and Drug Use Among Young People: Study Reveals Patterns of Use and the Most Vulnerable Groups in Brazil
A recent study involving more than 8,000 young Brazilians¹ revealed that alcohol and illicit drug use in the country is more frequent than indicated by previous surveys, especially among men, young people with lower levels of education, and those who report same-sex sexual experiences. The findings reinforce the central role of alcohol in patterns of polysubstance use and point to the urgent need for prevention and harm-reduction strategies that are more sensitive to social inequalities and the specific vulnerabilities of youth.
Alcohol consumption among young people and adolescents represents a significant public health problem worldwide, associated with greater exposure to risk behaviors and a range of negative health outcomes, such as unprotected sex, increased rates of teenage pregnancy, a higher risk of developing alcohol dependence in adulthood, deaths from traumatic causes, and impairments in cognitive and academic performance.
Studies in different countries, particularly in high-income nations, have indicated a trend toward reduced alcohol consumption among Generation Z youth, attributed both to increased abstinence in this age group and to lower levels of consumption among those who do drink.²
In Brazil, data from the 3rd National Survey on Alcohol and Drugs (LENAD III)³ showed that among adolescents aged 14 to 17 there was a consistent reduction, across all three survey waves, in both lifetime alcohol use and alcohol use in the previous year. Despite this trend, more than half of the Brazilian population (56%) tried alcohol before the legal age (18 years), and about one in four adolescents (25.5%) began regular consumption during this period. In addition, the study observed a significant decrease in binge drinking (five or more drinks on a single occasion), alongside an increase in the prevalence of heavy alcohol use (60 grams or more on a single occasion) among minors, highlighting the persistence of higher-risk drinking patterns.
In this context, a study recently published in Scientific Reports¹ analyzed the prevalence of and factors associated with alcohol and illicit drug use among Brazilian youth aged 16 to 25 years. The study employed a multicenter cross-sectional design, with data collected between 2016 and 2017 in all Brazilian state capitals and the Federal District.
A total of 8,581 young people participated, recruited mainly from Primary Health Care units. Information was obtained through structured face-to-face interviews conducted by trained professionals, addressing lifetime and past-year use of alcohol and illicit drugs, as well as sociodemographic, educational, economic, and behavioral variables.
The results showed that 71.6% of respondents reported lifetime alcohol use, and 66.5% reported alcohol consumption in the past year. About 30% had used at least one illicit drug, with cannabis being the most prevalent (27.4%), followed by cocaine (9.9%). The study also identified important gender differences, with men showing higher prevalence for all substances analyzed: alcohol (77.8%) and cannabis (37.3%). Another key finding was the strong association between alcohol consumption and illicit drug use, reinforcing the role of alcohol in polysubstance use patterns among young people. For example, cannabis use was 36.2% among alcohol consumers versus 5.3% among non-consumers.
Regarding frequency patterns, about 23% of young people reported drinking alcohol more than once a week, indicating a regular pattern of use. For cannabis, a substantial proportion of daily use was observed, especially among men. Although the use of other illicit drugs—such as cocaine, hallucinogens, and inhalants—was more sporadic, these patterns remain associated with significant risks, particularly when combined with alcohol consumption.
Other associated factors identified in the study included relationship status: participants without a partner had higher rates of alcohol and hallucinogen use. Greater vulnerability was also observed among young people who reported same-sex sexual experiences, who showed higher prevalence of use for all substances. From a socioeconomic perspective, the study revealed that young people from higher economic classes consume more alcohol, while lower educational attainment was strongly associated with the use of more harmful drugs, especially cocaine, with prevalence ratios higher than those observed among youth with higher levels of education.
Despite its relevance, the study has limitations. The cross-sectional design prevents causal inferences, and the sample restricted to young people receiving care in health services in capital cities limits the generalizability of the findings. In addition, the lack of data on consumption intensity or dependence restricts analyses of severity, although face-to-face interviews may have reduced underreporting bias.
Nevertheless, the study provides evidence that alcohol and illicit drug use among young Brazilians is high and unequal, disproportionately affecting certain social groups. The findings reinforce the need for more targeted prevention and harm-reduction strategies that take into account gender, educational level, social context, and sexual diversity.
References:
Zolpidem and Alcohol: From a Dangerous Combination to the Risk of Dependence
The concomitant use of alcohol and Z-drugs, such as zolpidem, poses significant health risks that go beyond the immediate interaction with alcohol, extending to an increased vulnerability to the development of long-term substance-related problems.
So-called Z-drugs are a class of medications widely used for the short-term treatment of insomnia and other sleep disorders.¹ This term includes drugs such as zolpidem, zopiclone, and eszopiclone. They were originally developed as alternatives to benzodiazepines, with the aim of providing sedative–hypnotic effects with lower risks of dependence and side effects. However, recent evidence challenges this perception of safety, suggesting that the risk profile for the subsequent development of alcohol- and drug-related problems is comparable between individuals who initiate treatment with benzodiazepines and those who start with Z-drugs.²
The mechanism of action of Z-drugs involves the selective stimulation of GABA-A receptors in the brain. This effect amplifies the activity of the neurotransmitter GABA, inhibiting neuronal excitability and inducing sleep.³ However, studies indicate that this allosteric modulation of GABA-A receptors also affects neural circuits involved in the behavioral effects of drugs of abuse, such as reward and reinforcement systems. This mechanism is shared by alcohol, which also increases GABA-A receptor activity, helping to explain the potential transition from medical use to misuse or the dangerous combination of these substances.
The concomitant use of alcohol and Z-drugs, such as zolpidem, presents immediate and severe risks. Because alcohol potentiates the sedative effects of these medications, combined use can result in excessive sedation and respiratory depression. According to the FDA, this combination increases the occurrence of complex sleep-related behaviors, in which individuals may walk, drive, or perform other activities while unconscious (sleepwalking), with no subsequent memory of the event (amnesia). For this reason, activities requiring full alertness should be avoided, and mixing these medications with alcohol is contraindicated.⁴
Beyond the immediate dangers of the interaction, new evidence suggests that the initiation of zolpidem treatment itself may represent a turning point for a patient’s long-term health. A large study published in 2025² indicated that patients who begin using Z-drugs have an increased risk—approximately twice as high for drug-related problems and 1.5 times higher for alcohol-related problems—compared with those who do not use these medications. This risk exists even among individuals with no prior history of dependence and is associated with severe outcomes, including not only substance use disorders but also unintentional intoxications, deaths, and suspected criminal offenses related to substance use.
To minimize these risks, ANVISA changed the prescription requirements for zolpidem in 2025, implementing stricter controls due to the risk of dependence and abuse.⁵ Therefore, it is essential that the use of these medications be restricted to the short term and accompanied by continuous medical supervision. Monitoring patients’ substance-use behaviors should be ongoing, not only during the period of prescription but also after treatment initiation, in order to prevent serious health and social consequences.
References